A.P. Pharma: Side Effect Issue With Competitive Drug Is A Huge Positive

Mon, 07/02/2012 - 07:18 EDT - Seeking Alpha

By Smith On Stocks:
Investment Thesis
The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to QT interval prolongation; this condition can cause abnormal heart rhythms that in some cases may be life threatening. This follows a previous communication on the same concern on September 11, 2011. Because AP Pharma's (APPA.OB) competitive product in development, APF530, is not linked to QT interval prolongation, this gives APF530 a meaningful differentiation from ondansetron in terms of safety. In addition, ondansetron can no longer be given as a single 32 mg infusion and will now have to be given in roughly three infusions over a twelve hour period. Some contacts I have spoken with think that these factors will cause a major erosion in ondansetron sales. If their assessment is correct, this could be a huge positive for A.P. Phama as ondansetron currently accounts for one thirdComplete Story »

Original article
Login to post comments

FDA Issues Warning That Misuse, Abuse Of Imodium Can Cause Heart Issues
Following reports that some opioid addicts are taking potentially lethal doses of over-the-counter anti-diarrhea medication, the Food and Drug Administration has issued a warning about the dangers of abuse and misuse of these seemingly innocuous products.
FDA Warns Of Rare, Potentially Dangerous Hypersensitivity To Popular Acne Products
(Paxton Holley)
FDA orders safety studies from scope manufacturers
WASHINGTON (AP) — Federal health authorities are ordering manufacturers of specialized medical scopes to study how the reusable devices are cleaned following a series of life-threatening bacterial outbreaks at U.S. hospitals.The Food and Drug Administration said Monday that the three companies must submit plans to study how well hospital staffers actually follow instructions for disinfecting the scopes between uses. The agency hopes this information will shed light on a recent spate of infections involving antibiotic-resistant "superbugs" linked to the scopes.
After FDA Warning, Kim Kardashian Posts Corrected Endorsement Of Morning Sickness Pill
FDA Approves First “Biosimilar” Drug. Could Drive Down Cost Of Most Expensive Medications
(D O’Quinn)
Dick Cheney Once Feared Terrorists Might Wirelessly Send A Fatal Shock To His Heart
Cheney had heart device partially disabled to prevent a terrorist from sending a fatal shock WASHINGTON (AP) — Former Vice President Dick Cheney says he once feared that terrorists could use the electrical device that had been implanted near his heart to kill him and had his doctor disable its wireless function.
MS specialist accused of defaming heart surgeon in email about controversial ‘liberation’ treatment
The fiery medical debate over a controversial new treatment for multiple sclerosis has spilled into the civil courts, as a heart surgeon on one side of the disagreement sues a neurologist on the other for allegedly libeling him. The unusual lawsuit now appears headed to a jury hearing, after an Ontario court rejected Dr. Mark Freedman’s attempts to have the case quashed, saying partly there was evidence of malice by him that should be aired at trial.
Salads Sold At Red Lobster & Olive Garden Linked To Cyclospora Outbreaks In Two States
(Morton Fox)
A.P. Pharma: PDUFA Date On APF530 Looms And I Am A Buyer
By Smith On Stocks: Investment Opinion and Background
Vibex MTX: The Cherry On Top Of The Antares Investment Story
By Smith On Stocks: Investment Thesis

Main menu

Secondary menu

A.P. Pharma: Side Effect Issue With Competitive Drug Is A Huge Positive

Related

Latest

Markets Map

Follow Us

Secondary menu